Minoxidil in the treatment of androgenetic alopecia.

Abstract

The National Institutes of Health (US NIH, 2018) estimates that in the US approximately 50 million men and 30 million women suffer from AGA (also known as pattern hair loss). Minoxidil is the only topical drug for the treatment of both female and male pattern hair loss. In the US, minoxidil is approved over-the-counter (OTC) at a maximum concentration of 5%. In this review, we summarize the findings of the pivotal studies used in support of the drug's approval as well as recent discoveries and novel developments in the use of minoxidil for the treatment of AGA.

• Authors: Andy Goren, Ty Naccarato
• Journal: Dermatologic therapy (Dermatol Ther) Vol. 31 Issue 5 Pg. e12686 (09 2018) ISSN: 1529-8019 [Electronic] United States
• PMID: 30155952 (Publication Type: Journal Article, Review)
• Copyright: © 2018 Wiley Periodicals, Inc.

Chemical References

• Vasodilator Agents
• Minoxidil

Topics

• Alopecia (drug therapy)
• Humans
• Minoxidil (therapeutic use)
• Vasodilator Agents (therapeutic use)